en · de · es · fr · pt
cjc-1295-notes.peptides9000.com › Topic › Background And Molecular Features — Quick Reference

Background And Molecular Features — Quick Reference

By Editorial Desk · published 2026-06-21 · last reviewed 2026-07-07 · Topic

Everything below concerns Cyclic AMP. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2026-07-07. Numbers and descriptions here follow the published literature rather than marketing material.

Background and Molecular Features

The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.

CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.

Receptor Action and Clearance

Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.

Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.

Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.

Cjc-1295 at a glance

PropertyValueNotes
ClassSynthetic peptideGHRH receptor agonist
Sequence length29 amino acidsDerived from human GHRH
Molecular weightAbout 3368 Da without linkerAlbumin-binding form is heavier
AppearanceWhite to off-white lyophilized powderCommon form for research reference material
Typical storage-20 °C or below, desiccatedProtect powder from light and moisture

Analytical Measurement And Stability

Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.

Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.

Related pages on this site

CJC-1295 Structure And Mechanism

The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.

Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.

Notes from published material

Inquiries sent to the IDF regarding the experiences of these health care workers received a statement from a spokesperson that did not directly confirm whether investigations into the shootings of preteen children had been conducted or if any soldiers faced disciplinary action for firing at them. In response to claims alleging that the report was based on "fabricated evidence", The New York Times issued a statement defending the integrity of the piece, emphasizing that it had undergone rigorous editing and verification, including consultations with experts and the use of supporting photographs, which they deemed "too horrific for publication." De Volkskrant interviewed 17 doctors who had volunteered during the Gaza war. Fifteen of them reported seeing children with "a single gunshot wound to the head and/or chest." These doctors reported seeing 114 children injured this way. In response, former Commander of the Royal Netherlands Army Mart de Kruif told the paper, "If you're seeing a high number of gunshot wounds to the chest area and the head, that’s not collateral damage – that’s deliberate targeting." In one documented case, a girl was reportedly shot and killed while in her mother's arms. In June 2026, a 94-page report by the UN Independent International Commission of Inquiry on the Occupied Palestinian Territory concluded there were reasonable grounds to determine that Israeli forces directly targeted children in Gaza using snipers and quadcopter drones.

== Anatomy == The pericardium is a tough fibroelastic sac which covers the heart from all sides except at the cardiac root (where the great vessels join the heart) and the bottom (where only the serous pericardium exists to cover the upper surface of the central tendon of diaphragm). The fibrous pericardium is semi-rigid, while the serous pericardium is quite pliable. The same mesothelium that constitutes the serous pericardium also covers the heart as the epicardium, resulting in a continuous serous membrane invaginated onto itself as two opposing surfaces (over the fibrous pericardium and over the heart). This creates a pouch-like potential space around the heart enclosed between the two opposing serosal surfaces, known as the pericardial space or pericardial cavity, which is filled with a small amount of serous fluid to lubricate the heart's movements and cushions it from any external jerk or shock.

As is the case with most brain tumors, a major difficulty in treating DIPG is overcoming the blood–brain barrier. In the brain – unlike in other areas of the body, where substances can pass freely from the blood into the tissue – there is very little space between the cells lining the blood vessels. Thus, the movement of substances into the brain is significantly limited. This barrier is formed by the lining cells of the vessels as well as by projections from nearby astrocytes. These two types of cells are knitted together by proteins to form what are called "tight junctions". The entire structure is called the blood–brain barrier (BBB). It prevents chemicals, toxins, bacteria, and other substances from getting into the brain, and thus serves a continuous protective function. However, with diseases such as brain tumors, the BBB can also prevent diagnostic and therapeutic agents from reaching their target. Researchers and clinicians have tried several methods to overcome the blood–brain barrier:

One of the 4th Panzer Army commanders, Erich Hoepner, was executed for his role in the 20 July plot. Following the end of the war, one of the 4th Panzer Army former commanders, Hermann Hoth, was tried in the High Command Trial, one of the Subsequent Nuremberg Trials. Explaining his harsh measures against Jews and other civilians, he claimed that "it was a matter of common knowledge in Russia that it was the Jew in particular who participated in a very large extent in sabotage, espionage, etc." Hoth was found guilty of war crimes and crimes against humanity. On 27 October 1948, he was sentenced to 15 years in prison. In January 1951, the sentence was reviewed with no changes. Hoth was released on parole in 1954; his sentence was reduced to time served in 1957. None of the other commanders ever faced charges.

Sources: en.wikipedia.org

Background from the literature

Because peptide chains have a directionality conferred by their N-terminus and C-terminus, β-strands too can be said to be directional. They are usually represented in protein topology diagrams by an arrow pointing toward the C-terminus. Adjacent β-strands can form hydrogen bonds in antiparallel, parallel, or mixed arrangements. In an antiparallel arrangement, the successive β-strands alternate directions so that the N-terminus of one strand is adjacent to the C-terminus of the next. This is the arrangement that produces the strongest inter-strand stability because it allows the inter-strand hydrogen bonds between carbonyls and amines to be planar, which is their preferred orientation. The peptide backbone dihedral angles (φ, ψ) are about (–140°, 135°) in antiparallel sheets. In this case, if two atoms Cαi and Cαj are adjacent in two hydrogen-bonded β-strands, then they form two mutual backbone hydrogen bonds to each other's flanking peptide groups; this is known as a close pair of hydrogen bonds. In a parallel arrangement, all of the N-termini of successive strands are oriented in the same direction; this orientation may be slightly less stable because it introduces nonplanarity in the inter-strand hydrogen bonding pattern. The dihedral angles (φ, ψ) are about (–120°, 115°) in parallel sheets.

These hormones will cause the masculinization of the phenotypically indifferent organs. When exposed to testosterone, the genital tubercle elongates to form the penis. By fusion of the urogenital folds—elongated spindle-shaped structures that contribute to the formation of the urethral groove on the belly aspect of the genital tubercle—the urogenital sinus closes completely to form the spongy urethra and the labioscrotal swellings unite to form the scrotum. The secretion of testosterone during this phase plays a decisive role in the final shaping of the penis. After birth, testosterone levels drop significantly until puberty.

== Signs and symptoms == Symptoms seen on plants infected with this virus can vary depending on the plant. However typical symptoms include vein clearing, mottling, and necrotic lines or etching. Symptoms can occur on leaves and fruit and the plants can become stunted. Like other potyviruses, TEV makes viral inclusions that can be seen in the light microscope if properly stained. This particular potyvirus makes two kinds of inclusions that can be diagnostic in a known host. One of the inclusions is the cylindrical inclusions found in the cytoplasm of infected cells and the second inclusion is found in the nucleus. Neither inclusion type stains in the nucleic acid stain (AzureA). (Inclusions of tobacco etch virus in various hosts.)

Sources: en.wikipedia.org

Frequently asked questions

What is the difference between CJC-1295 and natural GHRH?

Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.

Why does one name cover two different peptides?

The label was first attached to the albumin-binding form during early development work. A shorter analog without the linker later became known by the same name in informal use. Published papers normally state which version was studied, so the methods section resolves the ambiguity.

Is CJC-1295 a steroid or a natural hormone?

It is a synthetic peptide rather than a steroid, and it does not occur naturally in the body. Its sequence is derived from a hypothalamic hormone called growth hormone-releasing hormone. It works as a receptor agonist rather than as a replacement for that hormone.

Which receptor does the compound target?

It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.

Network